Overview

* SI-BONE Inc Q2 2025 revenue grows 21.7%, beating analyst expectations, per LSEG data

* Gross margin improves to 79.8%, up 80 basis points yr/yr

* Co achieves positive adjusted EBITDA of $1 mln

Outlook

* SI-BONE ( SIBN ) expects 2025 revenue between $195 mln and $198 mln

* Company estimates full-year gross margin of 78.5% to 79.0%

* SI-BONE ( SIBN ) anticipates operating expenses to grow ~10%

* Company expects positive adjusted EBITDA for full-year 2025

Result Drivers

* PROCEDURE DEMAND - U.S. revenue growth driven by strong underlying procedure demand

* PHYSICIAN ENGAGEMENT - Growth in active U.S. physicians by ~25% contributed to revenue increase

* PRODUCT LAUNCHES - Adoption of new product launches accelerated revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $48.63 $48.10

Revenue mln mln (8

Analysts

)

Q2 Net -$6.15

Income mln

Q2 Gross 79.8%

Margin

Q2 Basic -$0.14

EPS

Q2 $45.81

Operatin mln

g

Expenses

Q2 -$7 mln

Operatin

g income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for SI-BONE Inc ( SIBN ) is $25.00, about 30.4% above its August 1 closing price of $17.39

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)